Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl

Add To Compare

previously known as Nippon India Pharma Dir DR until

NAV on January 01, 2025
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 8,638 cr
Turnover Ratio 16.09%
Expense Ratio 0.91%
Exit Load 1.00%if redeemed within
1 Months
0.00%if redeemed after 1 Months
Returns
  • 1M: 3.72%
  • 1Y: 34.90%
  • 3M: 1.58%
  • 3Y: 21.28%
  • 6M: 19.05%
  • 5Y: 31.51%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since almost 20 years) Kinjal Desai (Since over 6 years)
ISIN INF204K01I43
Fund Family Nippon India
P/E Ratio 39.15
P/B Ratio 6.61
Launch Date January 01, 2013
Benchmark BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs BSE Healthcare TR INR

Alpha 1.48
Beta 0.90
R-Squared 93.93
Info Ratio 0.08
Tracking Err 3.97
Sortino 1.750
Sharpe 0.959
Std Dev 14.954
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Dividends that would otherwise be paid out to investors are instead used to purchase more units in the fund. Not as tax efficient as Growth.

View Factsheet

-


Other plans of Nippon India Pharma


Other Equity funds by Nippon India